We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » CRAWFORD'S PLEDGE TO TAKE FIFTH COULD DERAIL PLAN B CHALLENGE

CRAWFORD'S PLEDGE TO TAKE FIFTH COULD DERAIL PLAN B CHALLENGE

May 10, 2006

Former FDA Commissioner Lester Crawford's tentative pledge not to testify about his role in the agency's decision-making regarding the controversial contraceptive Plan B could potentially derail a lawsuit forcing the FDA to approve the drug for OTC use, sources say.

Crawford is the only agency official that presided over Barr's OTC application for its Plan B contraceptive from January 2005 until the agency postponed the review in August of that year, said Nan Strauss, staff attorney for the plaintiff, the Center for Reproductive Rights (CRR). Because Crawford, a political appointee, took over for the agency staff that had previously had responsibility for this decision, his refusal to testify leaves a sizable gap in the FDA's reasoning for delaying its decision, she added.

"We are deeply troubled by the possibility that such an important matter of public health is being withheld from the public, from the watchful eye of the press and from a court's oversight," Strauss said. CRR now must determine "another way to have meaningful judicial oversight," she added.

Steven Galson, director of the Center for Drug Evaluation and Research, and Janet Woodcock, the FDA's deputy commissioner for operations, testified during April depositions that Crawford relieved them of their decision-making responsibilities in January 2005. Woodcock told CRR that she was cut out of decision-making at that time and Galson testified that he received no feedback or consultation on his recommendation that Plan B be provided OTC for women 17 years and older.

Before the group decides what its next step will be it must find out how broadly Crawford will assert his Fifth Amendment rights. CRR will not know this until Crawford's deposition on May 24, she added. "We'll have to wait and see what happens at the deposition, though, to know how this is going to play out," Strauss said.

Crawford's counsel first alerted Magistrate Judge Viktor Pohorelsky during an April 27 telephone hearing that the former commissioner would assert his Fifth Amendment right not to incriminate himself. The attorney, Barbara Van Gelder of Wiley Rein & Fielding, argued that Crawford would refuse to testify because he is facing potential federal grand jury criminal investigations into issues including Plan B and questions over his financial disclosure forms. (http://www.fdanews.com/did/5_92/)

KEYWORDS FDAnews Drug Daily Bulletin

Upcoming Events

  • 08Sep

    Organizing Data and Document Archives: Finding a Needle in a Haystack for FDA Inspections

  • 15Sep

    Califf’s Post-PDUFA, Post-COVID FDA Agenda: Key Developments, Insights and Analysis

  • 20Sep

    Building a World-Class Pharmaceutical Advertising and Promotion Review Program

  • 21Sep

    The FDA’s Focus on Clinical Data Integrity Throughout Product Development and Approval

  • 22Sep

    FDA’s New Quality Management System Regulation: What the Proposed Harmonization with ISO 13485 Means for Devicemakers

  • 11Oct

    1st Annual Quality Management vSummit

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • AngioDynamics Gets Expanded Clearance for Auryon Atherectomy System

  • Aura Biosciences Receives Fast Track Designation for Bladder Cancer Candidate

  • FDA Issues Update on Becton Dickinson’s Recall

  • FDA Grants Accelerated Approval to Enhertu for HER2-Mutant NSCLC

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing